317 related articles for article (PubMed ID: 28645211)
41. The Mechanism of Androgen Actions in PCOS Etiology.
Rodriguez Paris V; Bertoldo MJ
Med Sci (Basel); 2019 Aug; 7(9):. PubMed ID: 31466345
[TBL] [Abstract][Full Text] [Related]
42. Gene Expression in Granulosa Cells From Small Antral Follicles From Women With or Without Polycystic Ovaries.
Owens LA; Kristensen SG; Lerner A; Christopoulos G; Lavery S; Hanyaloglu AC; Hardy K; Yding Andersen C; Franks S
J Clin Endocrinol Metab; 2019 Dec; 104(12):6182-6192. PubMed ID: 31276164
[TBL] [Abstract][Full Text] [Related]
43. Amino acid and fatty acid metabolomic profile during fasting and hyperinsulinemia in girls with polycystic ovarian syndrome.
Cree-Green M; Carreau AM; Rahat H; Garcia-Reyes Y; Bergman BC; Pyle L; Nadeau KJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E707-E718. PubMed ID: 30753112
[TBL] [Abstract][Full Text] [Related]
44. Implicating androgen excess in propagating metabolic disease in polycystic ovary syndrome.
Kempegowda P; Melson E; Manolopoulos KN; Arlt W; O'Reilly MW
Ther Adv Endocrinol Metab; 2020; 11():2042018820934319. PubMed ID: 32637065
[TBL] [Abstract][Full Text] [Related]
45. Adipose Insulin Resistance in Normal-Weight Women With Polycystic Ovary Syndrome.
Dumesic DA; Phan JD; Leung KL; Grogan TR; Ding X; Li X; Hoyos LR; Abbott DH; Chazenbalk GD
J Clin Endocrinol Metab; 2019 Jun; 104(6):2171-2183. PubMed ID: 30649347
[TBL] [Abstract][Full Text] [Related]
46. Letter to the Editor: Tackling NAFLD in Adolescent Polycystic Ovary Syndrome: Reducing Liver Fat to Mimic Weight Loss.
de Zegher F; Ibáňez L
Hepatology; 2021 Apr; 73(4):1623-1624. PubMed ID: 33047337
[No Abstract] [Full Text] [Related]
47. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
[TBL] [Abstract][Full Text] [Related]
48. Excess androgen production in subcutaneous adipose tissue of women with polycystic ovarian syndrome is not related to insulin or LH.
Amer SA; Alzanati NG; Warren A; Tarbox R; Khan R
J Endocrinol; 2019 Feb; ():. PubMed ID: 30802211
[TBL] [Abstract][Full Text] [Related]
49. A study of ghrelin and leptin levels and their relationship to metabolic profiles in obese and lean Saudi women with polycystic ovary syndrome (PCOS).
Daghestani MH; Daghestani M; Daghistani M; El-Mazny A; Bjørklund G; Chirumbolo S; Al Saggaf SH; Warsy A
Lipids Health Dis; 2018 Aug; 17(1):195. PubMed ID: 30131073
[TBL] [Abstract][Full Text] [Related]
50. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
[TBL] [Abstract][Full Text] [Related]
51. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood.
Tata B; Mimouni NEH; Barbotin AL; Malone SA; Loyens A; Pigny P; Dewailly D; Catteau-Jonard S; Sundström-Poromaa I; Piltonen TT; Dal Bello F; Medana C; Prevot V; Clasadonte J; Giacobini P
Nat Med; 2018 Jun; 24(6):834-846. PubMed ID: 29760445
[TBL] [Abstract][Full Text] [Related]
52. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
53. Metabolomic Insight into Polycystic Ovary Syndrome-An Overview.
Rajska A; Buszewska-Forajta M; Rachoń D; Markuszewski MJ
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32659951
[TBL] [Abstract][Full Text] [Related]
54. Correlation Between Fecal Metabolomics and Gut Microbiota in Obesity and Polycystic Ovary Syndrome.
Zhou L; Ni Z; Yu J; Cheng W; Cai Z; Yu C
Front Endocrinol (Lausanne); 2020; 11():628. PubMed ID: 33013704
[No Abstract] [Full Text] [Related]
55. Hyperandrogenism and insulin resistance modulate gravid uterine and placental ferroptosis in PCOS-like rats.
Zhang Y; Hu M; Jia W; Liu G; Zhang J; Wang B; Li J; Cui P; Li X; Lager S; Sferruzzi-Perri AN; Han Y; Liu S; Wu X; Brännström M; Shao LR; Billig H
J Endocrinol; 2020 Sep; 246(3):247-263. PubMed ID: 32590339
[TBL] [Abstract][Full Text] [Related]
56. Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS.
Shorakae S; Ranasinha S; Abell S; Lambert G; Lambert E; de Courten B; Teede H
Clin Endocrinol (Oxf); 2018 Nov; 89(5):628-633. PubMed ID: 29992612
[TBL] [Abstract][Full Text] [Related]
57. Impaired Lipolysis, Diminished Fat Oxidation, and Metabolic Inflexibility in Obese Girls With Polycystic Ovary Syndrome.
Kim JY; Tfayli H; Michaliszyn SF; Arslanian S
J Clin Endocrinol Metab; 2018 Feb; 103(2):546-554. PubMed ID: 29220530
[TBL] [Abstract][Full Text] [Related]
58. Tempol ameliorates polycystic ovary syndrome through attenuating intestinal oxidative stress and modulating of gut microbiota composition-serum metabolites interaction.
Li T; Zhang T; Gao H; Liu R; Gu M; Yang Y; Cui T; Lu Z; Yin C
Redox Biol; 2021 May; 41():101886. PubMed ID: 33592539
[TBL] [Abstract][Full Text] [Related]
59. AKR1C2 and AKR1C3 expression in adipose tissue: Association with body fat distribution and regulatory variants.
Ostinelli G; Vijay J; Vohl MC; Grundberg E; Tchernof A
Mol Cell Endocrinol; 2021 May; 527():111220. PubMed ID: 33675863
[TBL] [Abstract][Full Text] [Related]
60. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.
Teede HJ; Misso ML; Costello MF; Dokras A; Laven J; Moran L; Piltonen T; Norman RJ;
Hum Reprod; 2018 Sep; 33(9):1602-1618. PubMed ID: 30052961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
